Immunitybio announces first participants have been enrolled in lung-map trial studying anktiva to activate nk and t cells in non-small cell lung cancer

Culver city, calif.--(business wire)--immunitybio, inc. (nasdaq: ibrx), a clinical-stage immunotherapy company, announced today that the first participants have been enrolled in a study that is part of an 800-site master protocol trial for non-small cell lung cancer (nsclc). the lung cancer master protocol trial (lung-map) includes a study of anktiva™ (n-803) plus keytruda (pembrolizumab) versus investigator choice of standard-of-care chemotherapy in patients with non-small cell lung cancer (ns
IBRX Ratings Summary
IBRX Quant Ranking